Your session is about to expire
← Back to Search
IHT for Mild Cognitive Impairment
Study Summary
This trial will test whether a breathing program can help improve mild memory loss.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I can breathe through a special mask with less oxygen.You should not have depression when you join the study.You are currently in another research study or have been in a study that involved low oxygen levels, like living at high altitudes or being in a hypoxia training program.My chronic conditions like high blood pressure or diabetes have been stable for at least 6 months.I can attend all required lab visits for tests.Your oxygen levels in your blood and brain need to be at a certain level when you are at rest.I have had a severe head or brain injury, or a stroke.I currently have COVID-19.I do not have uncontrolled chronic conditions like high blood pressure or diabetes.I am open to being assigned to either the treatment or the placebo group.I am between 55 and 79 years old and have been diagnosed with mild cognitive impairment.I am expecting to undergo major surgery or receive a transplant.I cannot go to the lab by myself.I am not willing to sign consent for a double-blinded trial.I have been diagnosed with depression recently.You are very uncomfortable wearing a facemask and react strongly to not having enough oxygen.I have been diagnosed with Alzheimer's dementia or struggle with daily tasks due to my condition, and my mental exams show advanced impairment.You have metal implants in your body or feel uncomfortable in small, enclosed spaces.I am a woman and have gone through menopause.
- Group 1: IHT Treatment
- Group 2: Sham-IHT control
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are octogenarians being admitted to participate in this venture?
"The requisite age for entry into this clinical trial lies between 55 and 80 years old."
Are volunteers being recruited for this experiment?
"Per clinicaltrials.gov, this experiment is actively recruiting participants. The first post was made on February 27th 2023 and the most recent update occurred April 3rd of that same year."
To what extent has enrollment in this research project been successful?
"Affirmative. Clinicaltrials.gov contains data that proves this clinical trial, initially shared on February 27th 2023, is actively recruiting participants. 66 patients must be signed up at a single medical centre to complete the research project."
Does my profile meet the qualifications necessary to join this scientific trial?
"This research trial is seeking 66 adults, aged 55 to 80 years old and with mild cognitive impairment. In order for patients to be eligible, they must meet the following criteria: men or women of appropriate age range who have been diagnosed with MCI; consenting to either treatment or sham-treatment control group; multiple visits capability; ability to comfortably breathe moderately hypoxic air through a specialised facemask; chronic conditions such as hypertension, coronary artery disease, diabetes etc.; no history of stroke nor obstructive sleep apnea; arterial oxygen saturation over 95% and cerebral tissue oxygenation above 50% during rest period (if female subject"
What key goals is this research seeking to achieve?
"This 5-week to 12-week intervention is intended to assess the primary objective of Visual Orientation and Executive Function. Secondary objectives include evaluating Brain Morphology (Thickness of cortical gray matter assessed by brain MRI), Neurotoxic Protein (Blood beta-amyloid assessed by enzyme-linked immunosorbent assay) , and Neuroprotective Protein (Blood erythropoietin assessed by enzyme-linked immunosorbent assay). Each outcome aims at detecting a better result through either increased or decreased concentrations, depending on the measure."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger